C. CONRAD JOHNSTON JR., M.D., F.A.C.P
This content is PDF only. Please click on the PDF icon to access.
It has been estimated that one out of every 100 to 150 persons over 45 years of age has Paget's disease of bone and that 80% of affected individuals have symptoms (1). Skeletal pain is the most frequent clinical manifestation, but pathologic fractures, neurological symptoms, hearing loss, heart failure, and, rarely, osteogenic sarcoma also occur. Many forms of therapy have been used including corticoids, salicylates, sodium fluoride, and neutral phosphate, but none has proved entirely satisfactory, either because of lack of prolonged effectiveness or because of drug toxicity. The lesion is characterized by an acceleration of both bone resorption and
JOHNSTON CC. Calcitonin in the Treatment of Paget's Disease of Bone. Ann Intern Med. ;76:665–666. doi: 10.7326/0003-4819-76-4-665_2
Download citation file:
Published: Ann Intern Med. 1972;76(4):665-666.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use